2nd Annual Chairs in Psychiatry Summit - The Master Class for Psychiatric Professional Development
Rahn Kennedy Bailey, MD, FAPA
Dr. Bailey is a dual board certified forensic psychiatrist. He completed his general psychiatric training at the University of Texas Medical School in June 1994. Thereafter, Dr. Bailey completed his forensic psychiatric fellowship at Yale University in June 1995. He became board certified in general psychiatry in March 1998. In April 1999, he achieved board certification in Forensic Psychiatry. Prior to the previous, Dr. Bailey served as tenure track professor on the medical faculty of Louisiana State University in New Orleans. He previously had clinical appointments at Tulane University School of Medicine and Baylor College of Medicine. Dr. Bailey has held positions as an Associate Professor at the University of Alabama-Birmingham and Past Director of Bryce Hospital in Alabama. Dr. Bailey currently serves as Chair & Interim Executive Director of the Department of Psychiatry and Behavioral Sciences at Meharry Medical College, School of Medicine in Nashville, TN. Dr. Bailey was the Psychiatry Section Chairman of the National Medical Association (NMA) from 2002-2006. Dr. Bailey has served as the Secretary to the House of Delegates of the NMA in 2006-2007. He was elected as the Vice Speaker in August, 2007 and currently serves the Association in this role. In addition, he is a member of the Administrative Council of the American Academy of Psychiatry and Law (AAPL). From 1998-2000, he served as the Corporate Medical Director of Continuum Healthcare, Inc. In that capacity, he managed the clinical responsibilities.
Prior to his current position, Dr. Bailey was a staff physician at Clear Lake Regional Hospital. He was previously the Medical Director/CEO of Bailey Psychiatric Forensic Associates and Research Institute. He oversees the clinical and forensic responsibilities of one physician, and three therapists. Additionally, he was the Chairperson for the Katrina Response Effort of the National Medical Association. In this capacity, he led teams of physicians in treating the mental health needs of those displaced by the devastating hurricanes.
Dr. Bailey is a national forensic expert, who has testified and participated in both civil, racial discrimination and criminal cases both locally and nationally. He has been retained for his expertise in forensic psychiatry by the State of Texas, where he conducts evaluations on Sexually Violent Predators (SVP).
David Baron, MSEd, DO
Dr. Baron is Professor and Chair of the Department of Psychiatry at Temple University School of Medicine. He is the current President of the Group for the Advancement of Psychiatry (GAP) and a member of the executive council of the AACDP. He currently chairs the WPA Section on Exercise, Psychiatry, and Sport. His current research interests are in ADHD, sports psychiatry, translational psychiatric education, and public mental health literacy.
William E. Bunney, Jr., MD
Dr. Bunney received his MD from the University of Pennsylvania Medical School and completed his residency in Psychiatry at Yale University School of Medicine. He held a number of positions at the National Institute of Health, including Section Chief, Lab Chief, and Acting Director of the Intramural Program of the NIMH and the Director of the Division of Narcotic Addiction and Drug Abuse. He now serves as Distinguished Professor and Della Martin Chair, Psychiatry, in the Department of Psychiatry and Human Behavior, School of Medicine, University of California at Irvine. He has received a number of national and international research awards including the Hofheimer Research Award, the International Anna-Monika Award and the NARSAD Nora Maddox Falcone Prize for Outstanding Achievement in Affective Disorders Research. He was elected to the Institute of Medicine of the National Academy of Sciences and recently designated a Lifetime National Associate of the NAS. He was also elected president of the West Coast College of Biological Psychiatry, the Psychiatric Research Society, the American College of Neuropsychopharmacology, and the CINP. He serves on the National Scientific Advisory Board of NARSAD, the Harvard International Brain Repository, and the WHO Expert Panel on Mental Health. He is a member of thirteen editorial boards. His major research interests involve studies of depressive illness and schizophrenia. These include behavioral studies of the efficacy and mode of action of psychopharmacological agents, brain imaging studies, molecular genetic research, and the investigation of brain circuitry abnormalities. Dr. Bunney is the author of more than 400 scientific publications and the editor of seven books.
Steven A. Epstein, MD
Dr. Epstein is Professor and Chair of the Department of Psychiatry of the Georgetown University School of Medicine and Chief of Service of the Department of Psychiatry of the Georgetown University Hospital. He has conducted NIH-funded research and published extensively in the area of psychosomatic medicine. In 2001, he was awarded a 1.1 million dollar grant from NIMH to study primary care physicians' decision-making in the evaluation and treatment of depression. Since arriving at Georgetown in 1990, he has been the recipient of teaching awards from residents and has continued an active clinical practice in psychiatry for the medically ill.
Dr. Epstein received his BA from Yale College and graduated from the University of Pennsylvania School of Medicine. After completing a residency in Psychiatry at Tufts-New England Medical Center, Dr. Epstein was a fellow in Consultation-Liaison Psychiatry at Georgetown. For the ten years prior to becoming Chair of the Department of Psychiatry, Dr. Epstein directed the hospital's Consultation-Liaison psychiatry service. In addition to his most recent NIMH grant, he was Principal Investigator on two other NIMH grants in this area. In 2002, he was elected to the American College of Psychiatrists and received an exemplary psychiatrist award from the National Alliance for the Mentally Ill. As a national leader in psychosomatic medicine, he was recently appointed to membership of the Psychosomatic Medicine Committee of the American Board of Psychiatry and Neurology and the Council on Psychosomatic Medicine of the American Psychiatric Association. He currently directs Georgetown's Psychosomatic Medicine fellowship. He also leads the Physician-Patient Communication Committee for Georgetown University Hospital.
Mark S. Gold, MD
Dr. Gold is the Donald Dizney Eminent Scholar, Distinguished Professor and Chair of Psychiatry. Prior to assuming the position as Chair he was a Distinguished Service Professor in the Departments of Psychiatry, Neuroscience, Anesthesiology, and Community Health & Family Medicine at the University of Florida College of Medicine. He is also a member of the McKnight Brain Institute. Dr. Gold was the first Faculty in the Division of Addiction Medicine and Chief of the Addiction Medicine Division.
Dr. Gold is a teacher of the year, researcher, and inventor who has worked for 35 years to develop models for understanding the effects of tobacco and other drugs on the brain and behavior. Dr. Gold has developed animal models which have led to new treatments for addicts and also conceptualized hypotheses that were more than novel but also yielded new approaches to treat patients. Under his leadership, the Division of Addiction Medicine at the University of Florida has grown from Dr. Gold in 1990 to 12 full-time clinical physicians treating drug abuse and dependence and an equal number of researchers with major funded projects and research groups in second hand exposure models, self-administration, functional brain imaging, public health, impaired professionals, genomics, proteomics, and nanotechnology.
Dr. Gold's pioneering work on the brain systems underlying the effects of opiate drugs led to a dramatic change in the way opiate action was understood. He was the senior author on the discovery paper and was awarded a patent for the discovery of new uses for clonidine which remains widely used for opiate withdrawal and pain management. During the mid-1980s Gold and colleagues developed a new theory for cocaine action in the brain. Gold's work on cocaine led to a complete change in thinking about cocaine's addiction liability and acute and chronic actions. His work in this area remains seminal and is considered by many as a classic example of translational science. Dr. Gold and colleagues have reported on the treatment and outcome of impaired health professionals, especially physicians, for decades. In 2005, Gold and co-workers were first to demonstrate that intravenously administered anesthetics and analgesics were exhaled and these controlled and dangerous substances are active in the air of operating rooms and other sites where given to patients. Over the past two decades, Dr. Gold has pioneered the hypothesis of hedonic overeating or pathological attachment to food as an addiction. This work is much less controversial now that many recognize the similarities between great food and compulsive overeating and other process addictions such as gambling and sex. Dr. Gold and his nanotechnology colleagues at the McKnight Brain Institute have been awarded recent patents for the invention of breath tests for propofol, drugs of abuse, and medications which someday may become as commonplace as breathalyzer for alcohol intoxication or blood testing. Dr. Gold has also been a co-inventor for the invention of breath tests for adherence, compliance, and therapeutic drug monitoring for medications used to treat epilepsy and other medical conditions.
Dr. Gold has been a leader at the university, state, national, and international level in drug abuse prevention, treatment advocacy, and research. Dr. Gold is an editor of the Journal of Addictive Disease, editorial board member of a number of journals, and reviewer for many, many more. He reviews more than 20 journal articles yearly. Dr. Gold is a member of the University of Florida College of Medicine's Alumni Board of Directors, Betty Ford Institute Board in Palm Springs, California and Washington University's Undergraduate Experience Board of Directors, and also serves on the Board of the Institute for Behavioral and Health in Bethesda, Maryland. Dr. Gold is a Phi Beta Kappa graduate of Washington University in St Louis where he also was awarded the 1989 Distinguished Alumni Award. He has served CASA as an expert panelist on four occasions, most recently on treatment efficacy and parity. He was an Honors Graduate of the University of Florida College of Medicine where he was also AOA and a Wall of Fame award recipient. Dr Gold was awarded the 2004 Conway Hunter Society Award, The American Academy of Addiction Psychiatry's Founders Award in 2005, and the prestigious annual Nelson J. Bradley, MD, lifetime achievement award by the NAATP at their 2006 Annual Conference. Gold has also received awards from DARE and DEA for decades of volunteer service. Dr. Gold has been awarded Exemplary Teaching and Minority Mentoring Awards from the University of Florida College of Medicine and an Inventor Award from the University of Florida's Office of Technology Transfer for the licensing of one of his patents. Dr. Gold has been listed as one of the Best Doctors« in America.
Since beginning his career in research at the University of Florida in 1970, he has been the author of over 900 medical articles, chapters, and abstracts in journals for health professionals on a wide variety of psychiatric research subjects, and twelve professional books including practice guidelines, ASAM core competencies, and medical text books for primary care professionals. He is also the author of 15 general audience books.
Stephen M. Goldfinger, MD
Dr. Goldfinger is a community psychiatrist whose career has focused on the treatment and rehabilitation of the most seriously disabled psychiatric patients. He is currently a Professor and the Chair of Psychiatry and Behavioral Sciences at the State University of New York, Downstate Medical Center, Brooklyn.
Dr. Goldfinger trained at Harvard College, Yale Medical School, and did his psychiatric residency at the University of California, San Francisco/Mt. Zion Hospital. During his twelve years in San Francisco, he served as the Director of the Emergency, Outpatient and Inpatient services at San Francisco General Hospital and as the Mental Health Director of S.F. Health Care for the Homeless. He then became Assistant Professor of Psychiatry at Harvard Medical School, and the Clinical Director of the Massachusetts Mental Health Center and the Principal Investigator of a $13 million grant examining models of housing for homeless individuals with serve mental illness. He moved (back home) to New York City in 1997, to Downstate Medical Center, where he "began" his career working in the Department of Psychiatry as a volunteer when he was fifteen!
Dr. Goldfinger is an expert on homelessness, schizophrenia, and treatment adherence in mental illness. He is the author or editor of over 100 books, monographs, journal articles and abstracts, and on the editorial boards of numerous publications. Steve's entire career has focused on providing services to the most severely disenfranchised and disaffiliated populations. His most current area of study is the relationship between medication efficacy, therapeutic alliances, and the effectiveness of medication interventions. He is a tireless advocate for the most severely ill of our patients...serving as an active member of the National Alliance for the Mentally Ill (where he is the clinician who has covered their annual meeting for the past 20 years) and was a co-writer of a full-length documentary "I'm Still Here: The Truth about Schizophrenia".
Ned H. Kalin, MD
Dr. Kalin is Hedberg Professor and Chairman of the Department of Psychiatry at the University of Wisconsin School of Medicine and Public Health. He is Director of HealthEmotions Research Institute and Professor in the Department of Psychology at the University of Wisconsin. Dr. Kalin is an affiliate scientist at the Wisconsin Regional Primate Center and the Harlow Primate Laboratory. He serves as the principal investigator for several ongoing NIH-funded research projects, consults to the pharmaceutical industry for new drug development in psychopharmacology, and founded a biotechnology company, Promoter Neurosciences, aimed at developing novel gene-based treatments for psychiatric disorders. His research focuses on uncovering basic mechanisms that relate stress to the development of psychopathology and to understanding which mechanisms cause some children to be vulnerable for the development of anxiety and depression. In addition to his research activities, he treats patients that suffer from anxiety and depression that are refractory to standard treatment.
Dr. Kalin earned his medical degree from Jefferson Medical School in Philadelphia, Pennsylvania. He then did a residency in the Department of Psychiatry at the University of Wisconsin. Subsequently, he did a fellowship in Neuropsychopharmacology at the National Institute of Mental Health. Dr. Kalin is board certified by the American Board of Psychiatry and Neurology. He is a fellow of the American College of Neuropsychopharmacology and the American College of Psychiatry. He has been recognized for numerous awards including the 1985 A.E. Bennett Award for basic science research in biological psychiatry, the 2005 Edward A. Strecker Award, the 2007 American College of Psychiatrists Award for research in mood disorders, and the 2007 Gerald Klerman Senior Investigator Award. He recently served as president of the International Society of Psychoneuroendocrinology and also recently served on the National Advisory Mental Health Council. He has published over one hundred and seventy peer-reviewed research papers and is Co-Editor of the journal Psychoneuroendocrinology. He lectures regularly at national and international meetings.
Jerald Kay, MD
Dr. Kay graduated from the University of Maryland School of Medicine and completed his general and child and adolescent psychiatry residencies at the University of Cincinnati. He is a graduate and faculty member of the Cincinnati Psychoanalytic Institute. Dr. Kay is a Fellow of the American College of Psychiatrists and Distinguished Life Fellow of the American Psychiatric Association and has served as the chair of the APA Committee on Medical Student Education, the Council on Medical Education and Career Development, the Vestermark Award Board, and the Committee on the Practice of Psychotherapy. He chairs the World Psychiatric Association Task Force on Undergraduate and Post Graduate Curriculum as well as the APA Committee on College Mental Health. Dr. Kay is the immediate past chair of the Psychiatry Residency Review Committee of the ACGME and the Founding Editor of the Journal of Psychotherapy Practice and Research and Associate Editor of the American Journal of Psychotherapy. He has published extensively on the topics of medical and psychiatric education, medical ethics, child psychiatry, psychoanalysis, psychotherapy, the neurobiology of psychotherapy, and psychosocial aspects of AIDS and of cardiac transplantation. He is the editor of multiple books published by the American Psychiatric Press and John R. Wiley. Dr. Kay serves as the Associate Director of the Comprehensive Neuroscience Center at Wright State University. He is the recipient of the 2001 APA Seymour Vestermark Award for contributions to psychiatric education. Dr. Kay's current research examines fMRI in borderline personality disordered patients with self-harm behavior.
Martin B. Keller, MD
Dr. Keller was the Mary E. Zucker Professor and Chairman of the Department of Psychiatry and Human Behavior (DPHB) at Brown Medical School, and Executive Psychiatrist-in-Chief at the seven Brown affiliated hospitals, from 1989 until June 30th, 2009; where he currently serves as Professor in the DPHB.
For three decades Dr. Keller has been a pioneer in prospective, longitudinal, naturalistic, and neuropsychopharmacologic treatment research, including the development of new assessment methods (e.g., The Longitudinal Follow-up Evaluation) which have become standard in the field and have been used in over 1,500 research programs in the USA and internationally. Dr. Keller's studies led to a paradigm shift in understanding that mood and anxiety disorders are not short-lived episodes, but are primarily chronic, recurrent, and disabling illnesses, expressed across the lifespan. He discovered that about 25% of major depressive episodes were superimposed on dysthymia, a condition labeled "double depression." Subsequently replicated, the course of double depression is more problematic, chronic, and disabling than any other form of MDD. He first identified the serious under treatment of MDD in 1982. He applied these findings and methodologies to empirically develop new treatment strategies for bipolar disorder, recurrent MDD, and chronic MDD. Examples include: 1) the first demonstration of both the persistence of sub-syndromal symptoms in patient's who recovered from bipolar episodes while on lithium carbonate and that these symptoms conveyed a significantly greater risk of recurrence than patients who were euthymic; and that patients on standard blood levels of lithium had a significantly lower likelihood of recurrence than patients on lower doses; 2) the initial finding of the efficacy of antidepressants for acute, continuation and maintenance treatment of chronic major and double depression; and 3) the seminal study that the combination of pharmacotherapy and structured psychotherapy had a highly significantly greater rate of recovery (85%) in treating chronic forms of major depression over 12 weeks than pharmacotherapy (55%) or psychotherapy (52%) alone.
Dr. Keller is the recipient of the 1997 Award for Research in Psychiatry from the American Psychiatric Association; the 1998 National Alliance for Research on Schizophrenia and Depression (NARSAD) Lieber Award for research on the causes, pathophysiology, treatment, and prevention of depression; the 1999 Klerman Lifetime Research Award from the National Depression and Manic Depression Association; the 2001 American College of Psychiatrists (ACP) Mood Disorders Lifetime Research Award; the Edward A. Strecker Award from Pennsylvania Hospital and the University of Pennsylvania Health System for his outstanding contribution to the field of clinical psychiatry; and the Voice of Mental Health Award from the JED Foundation (2005) for research and other contributions in the area of suicide prevention.
Anand Kumar, MD
Dr. Kumar is Professor and Head of the Department of Psychiatry at the University of Illinois at Chicago. Dr. Kumar received his MD degree from Madras Medical College in Madras, India. He completed his residency training in psychiatry at the University of Medicine and Dentistry, New Jersey, and at the University of Michigan, Ann Arbor, and subsequently served as a Medical Staff Fellow in the Laboratory of Neurosciences at the NIH National Institute on Aging. Dr. Kumar's research focuses on late-life depression and mental disorders of the elderly, including Alzheimer's disease. He has served as Treasurer, Program Committee Chair and, from 2004 to 2005, President of the American Association for Geriatric Psychiatry. Dr. Kumar is Associate Editor of the American Journal for Geriatric Psychiatry, and has served as reviewer for numerous NIH review boards, including the Silvio Conte Translational Neuroscience Review Committee, the Clinical Neuroscience and Biological Psychopathology Review Committee, and the Neurology A Review Committee. He has been fully funded by NIH research grants for over 18 years, and is author or co-author of more than 125 peer-reviewed journal articles and book chapters. Dr. Kumar is renowned in geriatric psychiatry as an educator and mentor; his former trainees have been awarded clinical, research, and/or training positions at such esteemed institutions as UCLA, Brown, Emory, Duke, Johns Hopkins, Harvard, and Yale University.
Gail A. Mattox, MD, FAACAP
Dr. Mattox currently serves as Chairperson of the Department of Psychiatry and Behavioral Sciences at Morehouse School of Medicine and holds the rank of Professor of Clinical Psychiatry. She joined the faculty at Morehouse School of Medicine in 1989 and was appointed Chair of the Department in 2000.
Dr. Mattox received a BS degree with honors from Elmhurst College in Elmhurst, IL, and an MD degree with honors from Meharry Medical College in Nashville, TN. She completed a Pediatric Residency at Hubbard Hospital in Nashville, TN, followed by a Child Psychiatry Fellowship and General Psychiatry training at Northwestern University School of Medicine in Chicago, IL.
Dr. Mattox is a Diplomate of the American Board of Psychiatry and Neurology with additional sub-specialty Board Certification in Child and Adolescent Psychiatry. She is a Fellow of the American Academy of Child and Adolescent Psychiatry and a member of Alpha Omega Alpha Medical Honor Society.
Dr. Mattox is actively involved in numerous professional and community organizations. She is often invited to speak locally and nationally on a variety of mental health topics. She is the recipient of several awards for leadership, teaching, and community service.
W. Vaughn McCall, MD, MS
Dr. McCall is presently Professor and Chairman of the Department of Psychiatry and Behavioral Medicine at the Wake Forest University School of Medicine. He completed his medical degree and post-graduate psychiatric training at Duke University. He completed a Masters degree in Epidemiology from Wake Forest University. Dr. McCall is board certified in general psychiatry, geriatric psychiatry, and sleep disorders medicine. His research interests include depression, electroconvulsive therapy, quality of life, and insomnia. His research has been continuously funded by the National Institute of Mental Health since 1995, and he is author of more than 120 peer-reviewed journal articles. He is Editor of the Journal of ECT, Past President of the Association for Convulsive Therapy, and a prior Director of the Board of the American Academy of Sleep Medicine.
Merry Noel Miller, MD
Dr. Miller is Professor and Chair of the Department of Psychiatry and Behavioral Sciences at James H. Quillen College of Medicine, East Tennessee State University. She received her undergraduate education at Rhodes College in Memphis where she graduated Phi Beta Kappa with a BS in Biology. She received both a Master's Degree in Biochemistry and an MD degree from the University of Tennessee Center for Health Sciences in Memphis. She then did her residency training in Psychiatry at Duke University, followed by a brief period as a faculty member at Duke. She then moved to Chicago where she worked for seven years as part of a private practice group and as Medical Co-Director of an adolescent inpatient unit. Dr. Miller came to ETSU as a faculty member in 1995, became Interim Chair in January 2001, and became Chair in May 2002. Her academic interests include women's mental health and eating disorders, and she has published in both of these areas.
Laura Roberts, MD
Dr. Roberts serves as Chairman and Charles E. Kubly Professor in the Department of Psychiatry and Behavioral Medicine at the Medical College of Wisconsin and is President of the American Association of Chairs of Departments of Psychiatry. She is a nationally recognized scholar and leader in ethics, psychiatry, medicine, and medical education. She is Editor-in-Chief for the journal Academic Psychiatry and serves as an editorial board member and peer reviewer for many scientific and education journals. Dr. Roberts has competed for and received more than $10 million in federal and private research funds to study key questions in ethics, such as in the area of genetics ethics. A dedicated writer, she has written extensively on professionalism, clinical and research ethics, informed consent, clinical medicine, rural health care, health disparities, educational scholarship, end-of-life care, and physician and medical student health care. She has recently developed several books, including Concise Guide to Ethics in Mental Health Care, Professionalism and Ethics: Q & A Self-Study Guide, Handbook of Career Development in Academic Psychiatry and Behavioral Science, and The Book of Ethics: Expert Guidance for Professionals Who Treat Addiction.
David R. Rubinow, MD
Dr. Rubinow is the Assad Meymandi Professor and Chair of Psychiatry and Professor of Medicine at the University of North Carolina at Chapel Hill. Prior to assuming these positions, he was the Clinical Director of the NIMH from 1987-2006 and the Chief of the Behavioral Endocrinology Branch, NIMH from l996-2006.
Dr. Rubinow graduated from the University of Michigan, received his MD from the University of Connecticut, and completed an internship and residency at Yale University. In 1979, he began a clinical research fellowship in the Biological Psychiatry Branch at NIMH, in which he later served as Unit Chief and Section Chief. Additionally, from 1982-1989, he served as Director of the NIH Psychiatry Consultation-Liaison Service.
Dr. Rubinow's research interests have focused largely on the neurobehavioral effects of gonadal steroids. He has pursued these interests by employing hormone superagonists and receptor blockers to identify the central effects of gonadal steroids in isolation, particularly their effects on affective regulation in women and men. Dr. Rubinow's laboratory work has focused on sexual dimorphisms in neuronal and glial signal transduction as well as strain differences in behavioral sensitivity to gonadal steroids. Dr. Rubinow has received awards for his research (e.g., A.E. Bennett Neuropsychiatric Research Foundation Award, Research Award of the Academy of Psychosomatic Medicine, Gold Medal Award of the Society of Biological Psychiatry, Mood Disorders Research Award of the American College of Psychiatrists, and Menninger Award of the American College of Physicians), his clinical supervision and training (the NIH Distinguished Clinical Educator Award, NIMH Mentor of the Year) and his scientific administration (USPHS Outstanding Service Medal). He is a member of a number of professional organizations, including the Endocrine Society, the American College of Neuropsychopharmacology, of which he is the President-Elect, the American Neuroendocrine Society, and the Society of Biological Psychiatry, which he served as President and currently serves as Executive Secretary. Dr. Rubinow currently serves on the editorial boards of six journals and has authored or co-authored more than 300 scientific publications.
John Z. Sadler, MD
Dr. Sadler is the Daniel W. Foster Professor of Medical Ethics, a Distinguished Teaching Professor, and a Professor in the Departments of Clinical Sciences and Psychiatry at the University of Texas Southwestern Medical Center at Dallas. Dr. Sadler directs the Division of Ethics and Health Policy in the Department of Clinical Sciences, and the Division for Ethics in the Department of Psychiatry. Dr. Sadler is a chair of one of the institution's four Institutional Review Boards for the protection of human subjects in research and contributes to Southwestern's clinical and research ethics consultation services. A co-founder of the Association for the Advancement of Philosophy and Psychiatry (AAPP), he helped steward the founding of the Association's affiliated journal, Philosophy, Psychiatry, & Psychology (PPP), and continues to co-edit PPP with Bill Fulford, along with the Oxford University Press International Perspectives in Philosophy and Psychiatry book series. His philosophical research work in the philosophy and ethics of psychiatry has been supported with multiple federal and private foundation grants. He is the author of numerous peer-reviewed journal articles, chapters, and books. His most recent book, Values and Psychiatric Diagnosis, is the culmination of ten years' work on how values are involved in the design and content of psychiatric diagnostic classifications. In fall 2009, Oxford University Press will release a new book-length collaboration with philosopher Dr. Jennifer Radden, The Virtuous Psychiatrist: Character Ethics in Psychiatric Practice.
Alan F. Schatzberg, MD
Dr. Schatzberg received his MD from New York University in 1968. He did his psychiatric residency at the Massachusetts Mental Health Center from 1969-1972 and was Chief Resident, Southard Clinic in 1971-1972. He was also a Clinical Fellow in Psychiatry at Harvard Medical School.
After serving in the United States Air Force, he joined the staff at McLean Hospital and the Faculty of Harvard Medical School in 1974. At McLean Hospital, he held a number of important positions including Service Chief, Interim Psychiatrist in Chief, Co-Director of the Affective Disorders Program (with Dr. J. Cole), and Director of the Depression Research Facility. In 1988, he became Clinical Director of the Massachusetts Mental Health Center and Professor of Psychiatry at Harvard Medical School but continued at McLean Hospital with his research program on the biology and treatment of depression. In 1991, Dr. Schatzberg moved to Stanford University to become the Kenneth T. Norris, Jr., Professor and Chairman of the Department of Psychiatry and Behavioral Sciences.
Dr. Schatzberg has been an active investigator in the biology and psychopharmacology of depressive disorders. He has explored norepinephrine systems in depression as a means of subtyping these disorders. His research has also given us major insights into the biological mechanisms that underlie the development of delusions in major depression and is now opening exciting and innovative therapeutic strategies using glucocorticoid antagonists. Dr. Schatzberg has also been an active investigator in the clinical psychopharmacology of nondelusional depression with a particular recent interest in chronic depression. He has authored over 550 publications and abstracts, including the Manual of Clinical Psychopharmacology, whose sixth edition was published in 2007 and which is co-authored by Dr. Jonathan O. Cole and Dr. Charles DeBattista. He also co-edited with Dr. Charles B. Nemeroff the Textbook of Psychopharmacology, whose third edition appeared in late 2003. He is Co-Editor-in-Chief of the Journal of Psychiatric Research and sits on many other editorial boards as well, including the Archives of General Psychiatry, Journal of Clinical Psychopharmacology, Psychoneuroendocrinology, Biological Psychiatry, and others. He served as President of the American Psychiatric Publishing, Inc. from 2006 to 2008. He is a Past President of the American College of Neuropsychopharmacology and the Society of Biological Psychiatry, and is Secretary-General of the International Society of Psychoneuroendocrinology. He was awarded the 1998 Gerald L. Klerman, MD Lifetime Research Award from the NDMDA, the 2001 Gerald L. Klerman, MD Award from Cornell University Medical College, the 2001 Edward A. Strecker, MD Award from the University of Pennsylvania, the 2002 Mood Disorders Research Award from the American College of Psychiatrists, the 2002 American Psychiatric Association Award for Research, the Forum Award from the 3rd International Forum of Mood and Anxiety Disorders (IFMAD) in 2002, the 2005 Distinguished Service in Psychiatry Award from the American College of Psychiatrists, the 2005 Falcone Award from NARSAD, and the 2007 Chairman's Distinguished Scientist Award from Brown University. In 2003, he was elected into the Institute of Medicine of the National Academy of Sciences and in 2008 was elected President-elect of the American Psychiatric Association.
Russell E. Scheffer, MD
Dr. Scheffer is Chair and Professor of Psychiatry and Behavioral Sciences and Professor of Pediatrics at the University of Kansas School of Medicine-Wichita. He is board certified in Child, Adolescent, and General Psychiatry by the American Board of Psychiatry and Neurology. He has been acknowledged as one of the Best Doctors in America since 2005.
Dr. Scheffer received his MD from the University of Kansas Medical Center and holds an undergraduate degree in Human Biology from the University of Kansas. His post-graduate and fellowship training include an internship and residency in General Psychiatry at Dwight David Eisenhower Army Medical Center, Fort Gordon, GA, as well as a fellowship in Child, Adolescent and Family Psychiatry and Research Training in the Psychobiology of Psychotic Illnesses at the Medical College of Georgia in Augusta, GA.
Prior to coming to the University of Kansas School of Medicine-Wichita in June 2007, Dr. Scheffer served as associate professor of Psychiatry and Pediatrics, held the Chucker Airing Chair for Child and Adolescent Psychiatry, was the division director of Child and Adolescent Psychiatry in the Department of Psychiatry and Behavioral Medicine at the Medical College of Wisconsin, and was medical director of Psychiatry and Behavioral Medicine at the Children's Hospital of Wisconsin.
Recognized as an international and national presenter, Dr. Scheffer's research interests include psychopharmacology, bipolar disorder, psychotic disorders, ADHD, depression, pharmacogenomics, and neuroimaging. He has published numerous articles, books, and chapters.
As a member of the military, he served at the United States Military Academy, West Point, NY, and United States Army Reserves, Health Professions Scholarship Program. He served his military obligation at Fort Hood, TX, and Fort Gordon, GA.
S. Charles Schulz, MD
Dr. Schulz is the Hastings Endowed Chair and Head of the Department of Psychiatry at the University of Minnesota. He received his medical degree and psychiatric residency training from the University of California, Los Angeles. After his residency, he became a clinical associate in the Neuropsychopharmacology Section of the National Institute of Mental Health (NIMH).
In 1980, Dr. Schulz moved to the Medical College of Virginia where he started the Schizophrenia Program. His research interests focused on neuropsychiatric studies of teenagers suffering from schizophrenia, including CT research. He worked on the research team that investigated the é─˙low-dose neurolepticé─¨ strategy for borderline personality disorder. In 1983, he became Medical Director of the Schizophrenia Module at the University of Pittsburgh where his research focused on treatment-refractory schizophrenia. In 1986, he moved to the NIMH extramural program where he contributed to the National Plan on Schizophrenia Research. Along with Dr. Carol Tamminga, he started the biennial International Congress on Schizophrenia Research.
Dr. Schulz was Professor and Chairman of the Department of Psychiatry at Case Western Reserve University School of Medicine and University Hospitals from 1989-1999. His research interests included MRI imaging in adolescents with schizophrenia and bipolar illness. He has also has been active in clinical trials with antipsychotic medications.
At the University of Minnesota, Dr. Schulz' work has continued in brain imaging studies of both schizophrenic and borderline personality disorder patients as well as in treatment studies. Also, he has been active in planning the FIRST Program with the MIND Research Network.
Dr. Schulz has published over 100 articles in refereed journals, co-edited 6 books on schizophrenia, and edited Special Editions of Schizophrenia Bulletin and Psychopharmacology Bulletin. He has received numerous awards including the Kempf Fund Award for Research Development in Psychobiologic Psychiatry from the APA. Also, he has been recognized by NAMI with the Exemplary Psychiatrist Award.
Joel J. Silverman, MD
Dr. Silverman is the James A. Shield Jr., MD, Professor of Psychiatry and Chair of the Department of Psychiatry at the Medical College of Virginia at VCU in Richmond, Virginia. He has chaired this department since 1984. Born in Battle Creek, Michigan, he received his BA degree from Washington University in St. Louis, Missouri, in 1965, and his MD degree from University of Kansas Medical School in Kansas City, Missouri, in 1969. He completed a straight medicine internship in Chicago. He then performed psychiatric residency training at University of Kansas School of Medicine and was a Senior Resident and Fellow at Medical College of Virginia. Following residency training, Dr. Silverman was the Chief of Psychiatric Service at the U.S. Army Hospital, Camp Zama, Japan, from 1973-1975. Upon his return, he joined the faculty at the Medical College of Virginia.
Dr. Silverman serves on several American Psychiatric Association components including serving as Vice Chair of the Council on Medical Education and Lifelong Learning, and was a member of the Council on Advocacy and Public Policy. He serves as a consultant to the APA Scientific Program Committee. He served on the Committee on Public Funding for Psychiatric Services, served on the Consortium on Funding of the Council on Psychiatric Services, and served as Chair of the APA Corresponding Committee on Physician Health, Illness & Impairment. He was also a member of the Public Affairs Committee of the National Depressive/Manic Depressive Association, the Finance Committee of the Academy of Psychosomatic Medicine, and is a member of the VCU Health System Finance and Property Committee and the Board of MCV Physicians. In 1990, Dr. Silverman received the Distinguished Service Award from the APA District Branch, the Psychiatric Society of Virginia.
Dr. Silverman has received numerous honors and awards. He was the President of the American Association of Chairs of Departments of Psychiatry and was Chair of the Residency Review Committee in Psychiatry of the Accreditation Council of Graduate Medical Education.
Virginians for Mental Health Advocacy is a multidisciplinary advocacy group that Dr. Silverman founded in 1988. This organization wrote Virginia parity legislation and has been active in protecting the rights of citizens with mental illness. He has been a senior examiner for the American Board of Psychiatry and Neurology for many years.
In the area of research, Dr. Silverman has played an important role, building a strong research department. An Institute of Medicine psychiatry study chose to review the department as part of its study of departments that have built credible research programs.
Dr. Silverman regularly teaches medical students and almost yearly receives medical student teaching awards. He has built a strong residency training and medical student education program, and in 1975 founded the VCU/MCV division of Consultation/Liaison. In 2000, he was a School of Medicine nominee for VCU Distinguished Service Award. In 1999, he was named Fellow of the American College of Psychiatrists. In 1997, he was awarded the American Psychiatric Association Nancy G. A. Roeske Certificate of Recognition in Medical Student Education and is a Fellow of the American Psychiatric Association. He has been recognized in Best Doctors in America for many years.
Dr. Silverman was the Assistant Editor of Psychosomatics from 1986 to 1995 and has been a reviewer for American Journal of Psychiatry, Psychosomatics, Archives of General Psychiatry, and Journal of American Medical Association.
Stephen M. Strakowski, MD
Dr. Strakowski is the Dr. Stanley and Mickey Kaplan Professor and Chairman of Psychiatry at the University of Cincinnati College of Medicine, and the Chief of Psychiatry at University Hospital. He is also Professor of Psychology and Biomedical Engineering at the University of Cincinnati. Dr. Strakowski graduated summa cum laude from the University of Notre Dame with a BSE in 1984 and alpha omega alpha from Vanderbilt University School of Medicine with an MD in 1988. He completed his residency training at McLean Hospital/Harvard University School of Medicine in 1992. Upon completing that residency, he moved to the University of Cincinnati as an Assistant Professor, where he has remained and has been promoted to his current positions.
Dr. Strakowski now serves as the Chair for the Department of Psychiatry and the Director of the Center for Imaging Research. This latter core facility provides human research imaging (based upon an MRI platform) to the College of Medicine. Dr. Strakowski was also the founding Director of the Division of Bipolar Disorders Research at the University of Cincinnati College of Medicine. This program uses MRI neuroimaging, neurocognitive measures, and longitudinal outcome and treatment methods to study the neurophysiology and course of bipolar and related disorders. He has received/receives support from the NIMH, NIDA, the Stanley Medical Research Institute, NARSAD, and several pharmaceutical companies in this effort. Dr. Strakowski has received a number of awards, most notably the Gerald L. Klerman Award from the NDMDA and the Best Doctors in America for a number of years. He has over 200 peer-reviewed publications and a number of chapters, published abstracts, and solicited reviews. His work has been published in most major psychiatric journals including the American Journal of Psychiatry, and Archives of General Psychiatry, among others. He serves on several editorial boards and as the Field Editor for Neuroimaging for Bipolar Disorders.
Manuel Tancer, MD
Dr. Tancer is the chair of the Department of Psychiatry and Behavioral Neurosciences at Wayne State University (WSU) School of Medicine. He also jointly serves as psychiatrist-in-chief for the Detroit Medical Center (DMC), having leadership over all WSU and DMC research and clinical programs in psychiatry.
Dr. Tancer is a strong advocate for mental health research and clinical programs. He places emphasis on the role of research in improving clinical care and about clinical care informing research. He strongly believes that citizens need parity for mental health coverage, particularly in Michigan. Since mental health is finally being recognized as a serious medical specialty, quality and accessibility to services needs to be increased. Research and evidence-based medicine are the keys to developing quality systems of care.
Dr. Tancer's own research interests are the long-term consequences of MDMA (ecstasy) use, concurrent conditions like addiction/medical illnesses and bipolar disorder, which are difficult to treat in unison, social phobia, and individual differences in the effects of drugs and medications. He also has a particular interest in the use of functional (fMRI and MRS) brain imaging.
Thaddeus P. M. Ulzen, MD, FRCP(C)
Dr. Ulzen is Professor and Chairman of the Department of Psychiatry and Behavioral Medicine and Associate Dean for Academic Affairs at the University of Alabama School of Medicine (Tuscaloosa Campus).
He graduated with distinction from the University of Ghana Medical School in 1978 and joined the University of Toronto Psychiatry Residency Program in 1980. He obtained his Specialist Certificate in Psychiatry from the Royal College of Physicians and Surgeons of Canada and a Postgraduate Diploma in Child Psychiatry from the University of Toronto in 1984. He also completed additional training in Clinical Psychopharmacology at the Clarke Institute of Psychiatry, Toronto in 1985.
He joined the faculty at the University of Toronto in 1985 as Lecturer and later as Assistant Professor. He was appointed Psychiatrist-in-Chief of the George Hull Centre for Children and Families, Toronto in 1995.
He joined the Department of Psychiatric Medicine at the Brody School of Medicine at East Carolina University in 1997 as Associate Professor/Vice-Chairman and Director of the University Psychiatry Center. He served as Interim Chairman from 2001-2004. Dr. Ulzen is a Fellow of the Royal College of Physicians of Canada, Foundation Fellow of the Ghana College of Physicians and Surgeons and a Fellow of the American Psychiatric Association. He was awarded the Nancy C.A. Roeske Certificate of Excellence in Medical Education by the American Psychiatric Association in May 2002. In April 2007 he was a recipient of a Yale/Johnson & Johnson award as a Physician Scholar in International Health.
His academic interests include disruptive behavior disorders, incarcerated adolescents, paranoid spectrum disorders, mental retardation and mental health consultation to primary care physicians, and underserved geographical areas and the use of telemedicine in education and clinical service.
Daniel R. Weinberger, MD
Dr. Weinberger is Director of the Genes, Cognition, and Psychosis Program of the Intramural Research Program, National Institute of Mental Health, National Institutes of Health in Bethesda, Maryland. He attended college at the Johns Hopkins University and medical school at the University of Pennsylvania and did residencies in psychiatry at Harvard Medical School and in neurology at George Washington University. He is board certified in both psychiatry and neurology.
Dr. Weinberger's research at the NIMH has focused on brain mechanisms involved in the pathogenesis and treatment of neuropsychiatric disorders, especially schizophrenia. His work has defined dysfunctional neural systems in the brain that appear to underlie many of the clinical symptoms of the illness. He was instrumental in focusing research on the role of abnormal brain development as a risk factor for schizophrenia. His lab has identified the first specific genetic mechanism of risk for schizophrenia, and the first genetic effects that account for variation in specific human cognitive functions and in human temperament. In addition, he and his colleagues developed the first high fidelity animal model of schizophrenia. In 2003, Science magazine highlighted the genetic research of his lab as the second biggest scientific breakthrough of the year, second to the origins of the cosmos.
He is the recipient of many honors and awards, including the NIH Directors Award, The William K. Warren Medical Research Institute Award, the Adolf Meyer Prize of the American Psychiatric Association, the Research Prize of the World Federation of Societies of Biological Psychiatry, the Gold Medal Award of the Society of Biological Psychiatry, the Foundation's Fund Prize from the American Psychiatric Association, and the Lieber Prize of the National Alliance for Research on Schizophrenia and Affective Disorders. He is past president of the Society of Biological Psychiatry, past President of the American College of Neuropsychopharmacology, and has been elected to the Institute of Medicine of the National Academy of Sciences. He sits on the editorial boards of sixteen scientific journals. He has published over four hundred scientific articles and has authored or edited six books.
It is the policy of The University of Texas Southwestern Medical Center and CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. All decisions to invite faculty were made by The University of Texas Southwestern Medical Center and CME Outfitters, LLC, independent of any commercial interest. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. The University of Texas Southwestern Medical Center and CME Outfitters, LLC, have evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Bailey has disclosed that he receives research support, is on the speakers bureau, and serves as a consultant to Bristol-Myers Squibb Company, Eli Lilly and Company, and Ortho-McNeil, Inc.
Dr. Baron has disclosed that he receives grants from the National Institute on Drug Abuse and National Institute of Mental Health, and research support from Quintiles Transnational Corp. He serves as a consultant to the California Academy of Family Physicians, Eli Lilly and Company, the Singapore Institute of Mental Health, and the University of Cairo. He is a member of the Data Monitoring Team for Pfizer Inc. He has authored books published by University Press and Wiley Press.
Dr. Bunney has no disclosures to report.
Dr. Epstein has no disclosures to report.
Dr. Gold has no disclosures to report.
Dr. Goldfinger has disclosed that he receives research support from Avantis Medical Systems, Inc., Danippon Sumitomo Pharma, H. Lundbeck A/S, Janssen, LP, Pfizer Inc., and Roche Labs. He is on the speakers bureau and serves as a consultant to Teva Pharmaceutical Industries Ltd.
Dr. Kalin has disclosed that he serves on the advisory boards of AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, CeNeRx BioPharma, Corcept Therapeutics, Cyberonics, Inc., Elsevier, Eli Lilly and Company, Forest Laboratories, Inc., General Electric Corp (GE Healthcare), GlaxoSmithKline, Jazz Pharmaceuticals, Letters & Sciences, Neuronetics Inc., Novartis Pharmaceuticals Corporation, Otsuka America Pharmaceutical, Inc., Sanofi-aventis, Takeda International, and Wyeth Pharmaceuticals. He is a stockholder of Corcept Therapeutics and CeNeRx BioPharma. He is the owner of Promoter Neurosciences, LLC. He owns patents for promoter sequences for corticotropin-releasing factor CRF2alpha and method of identifying agents that alter the activity of the promoter sequences, promoter sequences for urocortin II and the use thereof, promoter sequences for corticotropin-releasing factor binding protein and use thereof, and has applied for a patent for a method for reducing CRF receptor mRNA.
Dr. Kay has no disclosures to report.
Dr. Keller has disclosed that he receives research support from Pfizer Inc. He serves on the advisory boards of Abbott Laboratories, Bristol-Myers Squibb Company, CeNeRx BioPharma, Cyberonics, Inc., Cypress Bioscience, Inc., Forest Laboratories, Inc., Janssen, L.P., Neuronetics Inc., Novartis Pharmaceuticals Corporation, Organon Pharmaceuticals USA Inc., and Pfizer Inc. He serves as a consultant to Abbott Laboratories, CeNeRx BioPharma, Cephalon, Inc., Cypress Bioscience, Inc., Cyberonics, Inc., Forest Laboratories, Inc., Janssen, L.P., JDS, Medtronic, Inc., Organon Pharmaceuticals USA Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Roche, Solvay Pharmaceuticals, Inc., and Wyeth Pharmaceuticals.
Dr. Kumar has no disclosures to report.
Dr. Mattox has no disclosures to report.
Dr. McCall has disclosed that he receives research support from Mini-Mitter Co., National Institute of Mental Health, Sanofi-aventis, Sealy, Inc., and Sepracor, Inc. He is on the speakers bureaus of Sanofi-aventis and Sepracor, Inc. He serves as a consultant to GlaxoSmithKline, Orexo AB, Sealy, Inc., Sepracor, Inc., and Somaxon Pharmaceuticals, Inc.
Dr. Miller has no disclosures to report.
Dr. Roberts owns Terra Nova Learning Systems (TNLS), a small company that develops science-based educational products.
Dr. Rubinow has disclosed that he receives research support from Foundation of Hope and the National Institutes of Health/National Institute of Mental Health. He serves as a consultant to Azevan Pharmaceutical, Inc. and Dialogues in Clinical Neuroscience. He is a stockholder of Amgen Inc. and the Vanguard Special Health Mutual Fund.
Dr. Sadler has disclosed that he is a stockholder of Johnson & Johnson Pharmaceutical Research & Development, LLC.
Dr. Schatzberg has disclosed that he serves as a consultant to BrainCells Inc., CeNeRx BioPharma, Corcept Therapeutics, Eli Lilly and Company, GlaxoSmithKline, Neuronetics Inc., Pfizer Inc., PharmaNeuroBoost, and Sanofi-aventis. He is a stockholder of BrainCells Inc., CeNeRx BioPharma, Corcept Therapeutics, Forest Laboratories, Inc., Merck & Co., Inc., Neurocrine Biosciences, Inc., Pfizer Inc., PharmaNeuroBoost, Somaxon Pharmaceuticals, Inc., and Synosis Therapeutics. He has received honorarium from Roche Labs. He is the named inventor on pharmacogenetic use patents on prediction of antidepressant response.
Dr. Scheffer has disclosed that he receives research support from Wyeth Pharmaceuticals. He serves as a consultant to AstraZeneca Pharmaceuticals LP.
Dr. Schulz has disclosed that he receives research support from AstraZeneca Pharmaceuticals LP and Eli Lilly and Company. He is on the speakers bureau and serves as a consultant to Eli Lilly and Company.
Dr. Silverman has no disclosures to report.
Dr. Strakowski has disclosed that the UC Academic Health Center receives research support from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Laboratories, Inc., Janssen, LP, Johnson & Johnson Pharmaceutical Research & Development, LLC, Martek Biosciences, National Alliance for Research on Schizophrenia and Depression, National Institute on Alcohol Abuse and Alcoholism, National Institute on Drug Abuse, Nutrition 21, Pfizer Inc., Repligen Corporation, Shire Pharmaceuticals, Somerset Pharmaceuticals, Inc., and the Thrasher Foundation. He is on the speakers bureau of the France foundation. He serves as a consultant to Pfizer Inc.
Dr. Tancer has no disclosures to report.
Dr. Ulzen has no disclosures to report.
Dr. Weinberger has no disclosures to report. All decisions to invite faculty, including Dr. Weinberger, were made by The University of Texas Southwestern Medical Center and CME Outfitters, LLC, independent of any commercial interest.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
The University of Texas Southwestern Medical Center, CME Outfitters, LLC, the faculty, and the commercial supporters of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Click here to return to the activity details page.
Questions about this CE activity? Call us at 877.CME.PROS (877.263.7767).